Immunesensor Is Developing Novel Medicines That Target The Cgascyclic Gmp Amp Synthasestingstimulator Of Interferon Genespathway Of The Innate Immune System To Treat Cancer And Autoimmune Diseasesthe Company Has Licensed Technologies From The Laboratory Of Drzhijianjameschenprofessor Of Molecular Biology At The University Of Texas Southwestern Medical Center And Investigator Of Howard Hughes Medical Institutedrchen Discovered Cgas And Its Product Cgampwhich Activates Sting To Stimulate Immune Responsesthese Discoveries Form The Technological Foundation Of Immunesensor Immunesensor S Lead Programimsa101 Is A Sting Activator Currently In Clinical Development For Cancer Therapy There Are Also Multiple New Drug Candidates Emerging From The Company Researchincluding An Exciting Cgas Inhibitor Program Designed To Suppress Overactivated Autoimmunity
